Embryo-Fetal Toxicity ZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during p ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.67, a high estimate of $28.00, and a low estimate of $10.00. Surpassing the previous average price target ...
US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...
Zymeworks (ZYME) has released an update. Don't Miss our Black Friday Offers: Zymeworks has achieved a significant milestone with the FDA’s accelerated approval of Ziihera, a dual HER2-targeted ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...
The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated ...
This event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific Officer, will feature: Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE) molecules, ...